Reduction of cardiac hypertrophy in TGR(mREN2)27 by angiotensin II receptor blockade

被引:0
|
作者
Bohm, M
Lippoldt, A
Wienen, W
Ganten, D
Bader, M
机构
[1] MAX DELBRUCK CTR MOL MED, D-13125 BERLIN, GERMANY
[2] DR KARL THOMAE GMBH, PHARMA RES A, D-7950 BIBERACH, GERMANY
关键词
heart hypertrophy; transgenic rats; hypertension; angiotensin II;
D O I
暂无
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
TGR(mREN2)27 is a transgenic rat harboring the murine Ren-2 gene and exhibit fulminant hypertension and marked heart hypertrophy. In order to study the role of angiotensin II in the increase of cardiac mass, these animals were treated with antihypertensive and non-antihypertensive doses of the angiotensin II receptor AT(1) antagonist Telmisartan for 9 weeks. All doses led to significant reductions of heart hypertrophy detected by the evaluation of the diameter of cardiac muscle bundles, We conclude from this study that cardiac hypertrophy in TGR(mREN2)27 is characterized by an increased volume of cardiomyocytes and an unchanged amount of fibrous tissue and that angiotensin II plays an important role in the mechanisms leading to this phenotype.
引用
收藏
页码:217 / 221
页数:5
相关论文
共 50 条
  • [21] ANGIOTENSIN AND BRADYKININ PEPTIDES IN THE TGR(MREN-2)27 RAT
    CAMPBELL, DJ
    RONG, P
    KLADIS, A
    REES, B
    GANTEN, D
    SKINNER, SL
    HYPERTENSION, 1995, 25 (05) : 1014 - 1020
  • [22] SEXUAL DIMORPHISM OF BLOOD-PRESSURE IN HYPERTENSIVE TRANSGENIC RATS TGR(MREN2)27 - THE ROLE OF ANDROGENS
    BACHMANN, J
    GANTEN, U
    STOCK, G
    GANTEN, D
    NIEREN-UND HOCHDRUCKKRANKHEITEN, 1992, 21 (11) : 599 - 601
  • [23] The hypertensive Ren-2 transgenic rat TGR(mREN2)27 in hypertension research - Characteristics and functional aspects
    Langheinrich, M
    Lee, MA
    Bohm, M
    Pinto, YM
    Ganten, D
    Paul, M
    AMERICAN JOURNAL OF HYPERTENSION, 1996, 9 (05) : 506 - 512
  • [24] CHRONIC DEXAMETHASONE TREATMENT SUPPRESSES HYPERTENSION DEVELOPMENT IN THE TRANSGENIC RAT TGR(MREN2)27
    DJAVIDANI, B
    SANDER, M
    KREUTZ, R
    ZEH, K
    BADER, M
    MELLON, SH
    VECSEI, P
    PETERS, J
    GANTEN, D
    JOURNAL OF HYPERTENSION, 1995, 13 (06) : 637 - 645
  • [25] ENHANCED ADRENAL RENIN AND ALDOSTERONE BIOSYNTHESIS DURING SODIUM RESTRICTION IN TGR (MREN2)27
    RUBATTU, S
    ENEA, I
    GANTEN, D
    SALVATORE, D
    CONDORELLI, G
    CONDORELLI, G
    RUSSO, R
    ROMANO, M
    GIGANTE, B
    TRIMARCO, B
    VOLPE, M
    AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 1994, 267 (04): : E515 - E520
  • [26] Exaggerated natriuresis in transgenic (mRen2)27 rats
    Schneider, K
    Gross, V
    Lippoldt, A
    Luft, FC
    JOURNAL OF HYPERTENSION, 1997, 15 (09) : 1041 - 1048
  • [27] Comparative analysis of telmisartan and olmesartan on cardiac function in the transgenic (mRen2)27 rat
    DeMarco, Vincent G.
    Johnson, Megan S.
    Habibi, Javad
    Pulakat, Lakshmi
    Gul, Rukhsana
    Hayden, Melvin R.
    Tilmon, Roger D.
    Dellsperger, Kevin C.
    Winer, Nathaniel
    Whaley-Connell, Adam T.
    Sowers, James R.
    AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2011, 300 (01): : H181 - H190
  • [28] Blockade of angiotensin II type 1 receptor and not of endothelin receptor prevents hypertension and cardiovascular disease in transgenic (mREN2)27 rats via adrenocortical steroid-independent mechanisms
    Rossi, GP
    Sacchetto, A
    Rizzoni, D
    Bova, S
    Porteri, E
    Mazzocchi, G
    Belloni, PS
    Bahcelioglu, M
    Nussdorfer, GG
    Pessina, AC
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2000, 20 (04) : 949 - 956
  • [29] Dissociation of blood pressure reduction from end-organ damage in TGR(mREN2)27 transgenic hypertensive rats
    Teisman, ACH
    Pinto, YM
    Buikema, H
    Flesch, M
    Böhm, M
    Paul, M
    van Gilst, WH
    JOURNAL OF HYPERTENSION, 1998, 16 (12) : 1759 - 1765
  • [30] INCREASED INTRACELLULAR SODIUM CONCENTRATION AND IMPAIRED SODIUM-TRANSPORT SYSTEMS IN TRANSGENIC RATS TGR(MREN2)27
    TEPEL, M
    THEILMEIER, G
    BACHMANN, J
    GANTEN, D
    RAHN, KH
    ZIDEK, W
    NIEREN-UND HOCHDRUCKKRANKHEITEN, 1993, 22 (07) : 355 - 357